These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1371908)

  • 21. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of interferon gamma on T lymphocytes from patients with multiple sclerosis.
    Grimaldi LM; Martino G
    Mult Scler; 1995; 1 Suppl 1():S38-43. PubMed ID: 9345397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant DNA-derived interferons-alpha and -beta modulate the alloactivated proliferative response of bulk and cloned human lymphocytes.
    Chen BP; Sondel PM
    J Biol Response Mod; 1985 Jun; 4(3):287-97. PubMed ID: 3160832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant interferon-alpha, -beta, and -gamma enhance the proliferative response of human B cells.
    Morikawa K; Kubagawa H; Suzuki T; Cooper MD
    J Immunol; 1987 Aug; 139(3):761-6. PubMed ID: 2439592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic interferon therapy of multiple sclerosis: the pros.
    Knobler RL
    Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seasonal variation of interferon-gamma production in progressive multiple sclerosis.
    Balashov KE; Olek MJ; Smith DR; Khoury SJ; Weiner HL
    Ann Neurol; 1998 Nov; 44(5):824-8. PubMed ID: 9818941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cell lymphokine-induced secretion of cytokines by monocytes from patients with multiple sclerosis.
    Maimone D; Reder AT; Gregory S
    Cell Immunol; 1993 Jan; 146(1):96-106. PubMed ID: 8425234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier.
    Niemelä J; Ifergan I; Yegutkin GG; Jalkanen S; Prat A; Airas L
    Eur J Immunol; 2008 Oct; 38(10):2718-26. PubMed ID: 18825744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic antiproliferative effects of human recombinant alpha 54- or beta ser-interferon with gamma-interferon on human cell lines of various histogenesis.
    Schiller JH; Groveman DS; Schmid SM; Willson JK; Cummings KB; Borden EC
    Cancer Res; 1986 Feb; 46(2):483-8. PubMed ID: 2416427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis.
    Young MR; Wright MA
    Cancer Res; 1992 Nov; 52(22):6335-40. PubMed ID: 1423279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis.
    Noronha A; Toscas A; Jensen MA
    J Neuroimmunol; 1993 Jul; 46(1-2):145-53. PubMed ID: 8360326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects.
    Lysandropoulos AP; Jaquiéry E; Jilek S; Pantaleo G; Schluep M; Du Pasquier RA
    J Neuroimmunol; 2011 Apr; 233(1-2):240-4. PubMed ID: 21186064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity.
    Antel JP; Arnason BG; Medof ME
    Ann Neurol; 1979 Apr; 5(4):338-42. PubMed ID: 312620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis.
    Porrini AM; De Luca G; Gambi D; Reder AT
    J Neuroimmunol; 1998 Jan; 81(1-2):109-15. PubMed ID: 9521612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of a suppressor T-cell pathway by interferon.
    Aune TM; Pierce CW
    Proc Natl Acad Sci U S A; 1982 Jun; 79(12):3808-12. PubMed ID: 6179085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis.
    Hirsch RL; Johnson KP
    J Interferon Res; 1986 Apr; 6(2):171-7. PubMed ID: 2941493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferons in multiple sclerosis. A review of the evidence.
    Panitch HS
    Drugs; 1992 Dec; 44(6):946-62. PubMed ID: 1282865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of interferons in demyelinating diseases.
    Arnason BG; Toscas A; Dayal A; Qu Z; Noronha A
    J Neural Transm Suppl; 1997; 49():117-23. PubMed ID: 9266421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.